Celldex Therapeutics, Inc.
CLDX· Nasdaq
Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001104659-26-057113
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $15.00K | $695.00K | $156.00K | $967.00K |
| Net Income | -$78.69M | -$53.80M | -$32.81M | — |
| EPS Diluted |
Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR
| -$1.18 |
| -$0.81 |
| -$0.56 |
| -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.